arrow
P

Paul M. Harari

university of wisconsin school of medicine and public health
H指数:72
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality of life in patients with p16+ oropharyngeal cancer receiving accelerated radiotherapy with either cisplatin or cetuximab in the NRG/RTOG 1016 randomized controlled trial

在NRG/RTOG 1016随机对照试验中,接受加速放疗并使用顺铂或西妥昔单抗治疗的p16阳性口咽癌患者的生活质量

2026-03-110
PRE
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience

头颈癌放射治疗期间的顺铂:NRG Oncology经验见解

2025-12-040
PRE
Self-Perceived Hearing Outcomes with Radiation and Cisplatin or Radiation and Cetuximab for Patients with HPV-Positive Oropharyngeal Cancer – Results from xxxxx

自评听力结局:HPV阳性口咽癌患者接受放疗联合顺铂或放疗联合西妥昔单抗治疗的结果——来自xxxxx的研究

2025-08-180
PRE
Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study
2025-01-010
OAAI
From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
2024-10-101
OAAI
Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade
2024-09-182
OA
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
2024-09-017
OAAI
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer : Toxicity and Ef fi cacy Results of a Phase 1b Trial
2024-04-013
OAAI
A platform-independent AI tumor lineage and site (ATLAS) classifier
2024-03-130
OAAI
Microphysiological model reveals the promise of memory-like natural killer cell immunotherapy for HIV± cancer (vol 14, 6881, 2023)
2023-11-100
OAAI
Microphysiological model reveals the promise of memory-like natural killer cell immunotherapy for HIV± cancer
2023-10-216
OAAI
Final Report of NRG Oncology RTOG 0022: A Phase 1/2 Study of Conformal and Intensity Modulated Radiation for Oropharyngeal Cancer
2023-10-014
OAAI